Ellie (Alice) Guardino

Administrative Appointments

• Director, Medical Informatics, Stanford Hospital and Clinics (2007 - present)

Honors and Awards

• The Mario Mollari Award for excellence in Microbiology and Immunology, Georgetown University Medical School (1997)
• Translation Cancer Research Award, AACR (2003)
• Genomics and Oncology, Yu and Bechmann Foundation (2004)
• Leventhal Scholar in Cancer Research, AACR (2004)

Professional Education

Graduate & Fellowship Program Affiliations

• Medicine
• Microbiology and Immunology

Community & International Work

• Advances in the Management of Breast Cancer, Philippines 

Current Research Interests

Dr. Guardino�s research pursuits have led to important discoveries in basic immunology and directly and indirectly to the development of immunotherapy�s for human diseases. She has studied the mechanisms by which the immune system recognizes foreign substances like viruses, microorganisms and cancer and the ways the immune system becomes deregulated and attacks �self� as seen in autoimmunity. Her research identified the cellular interactions involved in immune recognition and led to treatment strategies for cancer. She is investigating modulation of the immune system to recognize and kill cancer cells. Dr. Guardino�s studies are aimed at the development of biologic treatment approaches for cancer with less toxicity than standard chemotherapy.

Dr. Guardino is initiating a clinical trial combining a targeted biologic therapy with standard treatments prior to surgery in patients with high risk breast cancer. She is combining standard chemotherapy with a new biologic agent that targets HER2neu on breast cancer cells. The combination should disrupt proliferation pathways and growth of cancer cells. The goal is to improve tumor cell killing with little or no added side effects over chemotherapy alone. The trial also investigates new imaging modalities using breast MRI to monitor tumor responses. The trial will also integrate efforts in microarray analysis to examine genes expressed by the tumor cells. Dr. Guardino will evaluate tumor cell markers to better understand this disease.

Dr. Guardino has also initiated a clinical trial combining standard chemotherapy for metastatic breast cancer with a new and very promising biologic treatment for cancer targeting the development of new blood vessels (angiogenesis) which allows a cancer to grow and metastasize. Bevacizumab is a monocloncal antibody which inhibits the protein thought to regulate angiogenesis. By combining bevacizumab with chemotherapy without overlapping side effects she hopes to see...

Clinical Trials

• Phase I MVA-BN�-HER2 Vaccine in HER-2+ Breast CA Following Adjuvant Therapy Recruiting
• Radiation Therapy in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer Recruiting
• Suppression of Ovarian Function Plus Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer Recruiting
• A Pilot Study Evaluating the Immunologic Status of Patients with HER2+ Breast Cancer Completed
• A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Metastatic Breast Cancer Completed

Publications

• Phyllodes tumors of the breast: natural history, diagnosis, and treatment. Telli ML, Horst KC, Guardino AE, Dirbas FM, Carlson RW. J Natl Compr Canc Netw. 2007; 5 (3): 324-30
• Therapeutic vaccination against murine lymphoma by intratumoral injection of recombinant fowlpox virus encoding CD40 ligand. Liu A, Guardino A, Chinsangaram L, Goldstein MJ, Panicali D, Levy R. Cancer Res. 2007; 67 (14): 7037-44
• Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. Telli ML, Hunt SA, Carlson RW, Guardino AE. J Clin Oncol. 2007; 25 (23): 3525-33
• Production of myeloid dendritic cells (DC) pulsed with tumor-specific idiotype protein for vaccination of patients with multiple myeloma. Guardino AE, Rajapaksa R, Ong KH, Sheehan K, Levy R. Cytotherapy. 2006; 8 (3): 277-89
• A lower dose of thalidomide is better than a high dose in metastatic renal cell carcinoma. Srinivas S, Guardino AE. BJU Int. 2005; 96 (4): 536-9